The Technical Analyst
Select Language :

Sierra Oncology Inc [SRRA]

Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Sierra Oncology Inc is listed at the NASDAQ Exchange

-1.49% $18.56

Last updated: 21 Jan 2022 @ 11:25 am


FUNDAMENTALS
MarketCap: 279.42 mill
EPS: -7.16
P/E: 0.000
Earnings Date: Mar 09, 2022
SharesOutstanding: 15.06 mill
Avg Daily Volume: 0.0596 mill
RATING 2022-01-20
B
Neutral
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/203/204/201/212/213/21
Revenuen/an/an/an/a
Gr.Profitn/an/an/an/an/a
Ebit
Asset
Debt
DISCOUNTED CASH FLOW VALUE
$28.49
(53.50%) $9.93
Date: 2022-01-21

Insider Trading

Date Person Action Amount type
2021-11-24 Collard Craig A Buy 7 899 Common Stock
2021-11-23 Collard Craig A Buy 5 601 Common Stock
2021-06-08 Sinclair Andrew Buy 6 000 Stock Option (Right To Buy)
2021-06-08 Allen Andrew R Buy 6 000 Stock Option (Right To Buy)
2021-06-08 Ashiya Mona Buy 6 000 Stock Option (Right To Buy)
INSIDER POWER
91.46
Last 100 transactions
Buy: 16 891 499 | Sell: 112 473

Forecast: 13:03 - $18.17

Live Trading Signals (every 1 min)

Forecast 1: 11:33 - $18.62
Forecast 2: 12:23 - $18.21
Forecast 3: 13:03 - $18.17
SCORE
-1.50
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $18.56 (-1.49% )
Volume 0.0336 mill
Avg. Vol. 0.0596 mill
% of Avg. Vol 56.30 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Sierra Oncology Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Sierra Oncology Inc

RSI

Intraday RSI14 chart for Sierra Oncology Inc

Last 10 Buy & Sell Signals For SRRA

14 Signals | Accuracy: 14.29% | Accuracy Buy: 0.00% | Accuracy Sell: 28.57%

Avg return buy: -0.78 % | Avg return sell: -0.72 %

Date Signal @ Closed %
Jan 20 - 21:42sell$18.84N/AActive
Jan 20 - 21:25buy$19.00$18.84 @ Jan 20 - 21:42-0.84%
Jan 20 - 21:17sell$18.86$19.00 @ Jan 20 - 21:250.74%
Jan 20 - 15:02buy$18.86$18.86 @ Jan 20 - 21:170.00%
Jan 19 - 21:21sell$18.30$18.86 @ Jan 20 - 15:023.06%
Jan 19 - 21:06buy$18.30$18.30 @ Jan 19 - 21:210.00%
Jan 19 - 20:58sell$18.07$18.30 @ Jan 19 - 21:061.27%
Jan 19 - 20:42buy$18.29$18.07 @ Jan 19 - 20:58-1.20%
Jan 19 - 20:19sell$18.12$18.29 @ Jan 19 - 20:420.94%
Jan 19 - 19:48buy$18.64$18.12 @ Jan 19 - 20:19-2.79%
The Live Chart for Sierra Oncology Inc
Profile picture for
            Sierra Oncology Inc

SRRA

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Last 10 Buy Signals
Date Signal @
RCHGUJan 21 - 16:25$10.12
RCLFUJan 21 - 16:25$10.00
ALGSJan 21 - 16:25$3.06
XMRUSDJan 21 - 16:24183.08
UCBIOJan 21 - 16:24$27.44
MRTNJan 21 - 16:22$16.47
NEOUSDJan 21 - 16:2421.55
ADXUSDJan 21 - 16:240.430
SPJan 21 - 16:24$27.95
PEBOJan 21 - 16:24$32.74

Stock Peers

Company Price Change
SRRA18.56-1.49%
ALT7.193.30%
CUE8.880.57%
GRCL4.14-6.97%
LQDA5.72-0.52%
OPT7.16-0.14%
PRVB4.05-5.59%
PYXS9.48-0.32%
SABS5.64-3.18%
UTMD94.410.54%
VKTX3.960.13%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.